• FAQ
  • Glossary
Fermer

FAQ

Why are animal models used when testing the safety of a new therapy?
What role do preclinical and clinical trials play in ensuring patient safety?
Why are some conditions more suitable for gene and cell therapies than others?
There is an approved treatment available for my condition - why can't I receive it?
How to look for approved medicines?
How are medicines developed and approved?

Voir toutes les FAQ

Fermer

Glossary

Accelerated assessment
Adeno-associated virus (AAV)
Adenovirus
Adult stem cells
Advanced Therapy Investigational Medicinal Product (ATIMP)
Advanced Therapy Medicinal Product (ATMP)
Advertising 
Antibody
Antigen
Base editors

Voir le glossaire complet

CAR (Chimeric Antigen Receptor) T-Cell Therapy

Related topics:
Thérapie CAR-T

This program features topics relevant to the multidisciplinary team approach to caring for patients receiving CAR T-cell therapies and their relatives.

CAR (Chimeric Antigen Receptor) T-Cell Therapy

Remerciements et droits d'auteur

The CAR (Chimeric Antigen Receptor) T-cell therapies: a resource for healthcare professionals learning program was made possible by an educational grant from Celgene / Bristol Myers Squibb Company, Janssen-Cilag AG, Novartis and Kite Gilead.

HNHCP logo
Retour en haut de page
Le contenu de cette page vous a-t-il été utile ? Envoyez-nous vos commentaires